---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-006428"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:05:51.733704+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M

## Summary
- Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.
- Net loss of $2.0M ($0.05/shr) vs $2.5M ($0.09/shr) in same quarter prior year.
- Operating expenses flat at $2.6M; cash $9.0M plus $3.0M loan facility available.
- Lead candidate selonabant: IV formulation Phase 1 SAD study started Sep 2025; prioritizing pediatric pathway.
- Company cites cost savings from ending public reporting obligations as rationale for delisting.

## SEC filing metadata
- accession: 0001493152-26-006428
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/0001493152-26-006428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-006428
- JSON: https://secwatch.observer/filing/0001493152-26-006428.json
- Plain text: https://secwatch.observer/filing/0001493152-26-006428.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.